Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

ClinicalTrials.gov ID: NCT00657137

Public ClinicalTrials.gov record NCT00657137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane

Study identification

NCT ID
NCT00657137
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Tragara Pharmaceuticals, Inc.
Industry
Enrollment
12 participants

Conditions and interventions

Conditions

Interventions

  • apricoxib + lapatinib + capecitabine Drug
  • placebo + lapatinib + capecitabine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2008
Primary completion
Aug 31, 2009
Completion
Aug 31, 2009
Last update posted
Mar 14, 2012

2008 – 2009

United States locations

U.S. sites
44
U.S. states
20
U.S. cities
43
Facility City State ZIP Site status
Arizona Clinical Research Center Tucson Arizona
Comprehensive Blood and Cancer Center Bakersfield California
Alta Bates Summit Comprehensive Cancer Center Berkeley California
Bay Area Cancer Research Group, LLC Concord California
St. Jude Heritage Healthcare Fullerton California
Wilshire Oncology Medical Group Inc Inland Valleys/Pomona California
UCLA Los Angeles California
Olive View- UCLA Medical Center Olive View California
Cancer Care Associates Medical Group Inc Redondo Beach California
North America Research Institute San Dimas California
Central Coast Medical Oncology Corporation Santa Maria California
Front Range Cancer Specialists Fort Collins Colorado
Hematology Oncology Associates Lake Worth Florida
MD Anderson Cancer Center in Orlando Orlando Florida
Suburban Hematology-Oncology Associates Lawrenceville Georgia
Warren Billhartz Cancer Center Maryville Illinois
Mid-Illinois Hematology Oncology Associates Normal Illinois
Medical Consultants PC Muncie Indiana
SJMH Cancer Center Ann Arbor Michigan
Genesys Hurley Cancer Center Institute Flint Michigan
Foote Health System Jackson County Michigan
Bresline Cancer Center at Michigan State University Lansing Michigan
St. Mary Mercy Hospital Livonia Michigan
Mercy Hospital Port Huron Michigan
St. Mary's of Michigan Saginaw Michigan
St. Francis Cancer Treatment Center Grand Island Nebraska
Warren Hospital Phillipsburg New Jersey
San Juan Oncology Associates Farmington New Mexico
Flower Hospital Cancer Center Sylvania Ohio
University of Toledo Toledo Ohio
Samaritan Hematology and Oncology Consulting Corvallis Oregon
Providence Portland Medical Center Portland Oregon
Penn State Milton S Hershey Medical Center Hershey Pennsylvania
Eastern Regional Medical Center Philadelphia Pennsylvania
Associates in Hematology-Oncology PC Upland Pennsylvania
Charleston Oncology Hematology Associates Charleston South Carolina
Baptist Regional Cancer Center Knoxville Tennessee
University of Texas Medical Branch Galveston Texas
Jabboury Foundation for Cancer Research Inc Houston Texas
The Methodist Hospital Research Institute Houston Texas
Fletcher Allen Healthcare Inc. Burlington Vermont
Community Cancer Center at Rutland Regional Medical Center Rutland Vermont
Peninsula Cancer Institute Newport News Virginia
Madigan Army Medical Center Tacoma Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00657137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 14, 2012 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00657137 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →